Apoptosis
Apoptosis(凋亡)
As one of the cellular death mechanisms, apoptosis, also known as programmed cell death, can be defined as the process of a proper death of any cell under certain or necessary conditions. Apoptosis is controlled by the interactions between several molecules and responsible for the elimination of unwanted cells from the body.
Many biochemical events and a series of morphological changes occur at the early stage and increasingly continue till the end of apoptosis process. Morphological event cascade including cytoplasmic filament aggregation, nuclear condensation, cellular fragmentation, and plasma membrane blebbing finally results in the formation of apoptotic bodies. Several biochemical changes such as protein modifications/degradations, DNA and chromatin deteriorations, and synthesis of cell surface markers form morphological process during apoptosis.
Apoptosis can be stimulated by two different pathways: (1) intrinsic pathway (or mitochondria pathway) that mainly occurs via release of cytochrome c from the mitochondria and (2) extrinsic pathway when Fas death receptor is activated by a signal coming from the outside of the cell.
Different gene families such as caspases, inhibitor of apoptosis proteins, B cell lymphoma (Bcl)-2 family, tumor necrosis factor (TNF) receptor gene superfamily, or p53 gene are involved and/or collaborate in the process of apoptosis.
Caspase family comprises conserved cysteine aspartic-specific proteases, and members of caspase family are considerably crucial in the regulation of apoptosis. There are 14 different caspases in mammals, and they are basically classified as the initiators including caspase-2, -8, -9, and -10; and the effectors including caspase-3, -6, -7, and -14; and also the cytokine activators including caspase-1, -4, -5, -11, -12, and -13. In vertebrates, caspase-dependent apoptosis occurs through two main interconnected pathways which are intrinsic and extrinsic pathways. The intrinsic or mitochondrial apoptosis pathway can be activated through various cellular stresses that lead to cytochrome c release from the mitochondria and the formation of the apoptosome, comprised of APAF1, cytochrome c, ATP, and caspase-9, resulting in the activation of caspase-9. Active caspase-9 then initiates apoptosis by cleaving and thereby activating executioner caspases. The extrinsic apoptosis pathway is activated through the binding of a ligand to a death receptor, which in turn leads, with the help of the adapter proteins (FADD/TRADD), to recruitment, dimerization, and activation of caspase-8 (or 10). Active caspase-8 (or 10) then either initiates apoptosis directly by cleaving and thereby activating executioner caspase (-3, -6, -7), or activates the intrinsic apoptotic pathway through cleavage of BID to induce efficient cell death. In a heat shock-induced death, caspase-2 induces apoptosis via cleavage of Bid.
Bcl-2 family members are divided into three subfamilies including (i) pro-survival subfamily members (Bcl-2, Bcl-xl, Bcl-W, MCL1, and BFL1/A1), (ii) BH3-only subfamily members (Bad, Bim, Noxa, and Puma9), and (iii) pro-apoptotic mediator subfamily members (Bax and Bak). Following activation of the intrinsic pathway by cellular stress, pro‑apoptotic BCL‑2 homology 3 (BH3)‑only proteins inhibit the anti‑apoptotic proteins Bcl‑2, Bcl-xl, Bcl‑W and MCL1. The subsequent activation and oligomerization of the Bak and Bax result in mitochondrial outer membrane permeabilization (MOMP). This results in the release of cytochrome c and SMAC from the mitochondria. Cytochrome c forms a complex with caspase-9 and APAF1, which leads to the activation of caspase-9. Caspase-9 then activates caspase-3 and caspase-7, resulting in cell death. Inhibition of this process by anti‑apoptotic Bcl‑2 proteins occurs via sequestration of pro‑apoptotic proteins through binding to their BH3 motifs.
One of the most important ways of triggering apoptosis is mediated through death receptors (DRs), which are classified in TNF superfamily. There exist six DRs: DR1 (also called TNFR1); DR2 (also called Fas); DR3, to which VEGI binds; DR4 and DR5, to which TRAIL binds; and DR6, no ligand has yet been identified that binds to DR6. The induction of apoptosis by TNF ligands is initiated by binding to their specific DRs, such as TNFα/TNFR1, FasL /Fas (CD95, DR2), TRAIL (Apo2L)/DR4 (TRAIL-R1) or DR5 (TRAIL-R2). When TNF-α binds to TNFR1, it recruits a protein called TNFR-associated death domain (TRADD) through its death domain (DD). TRADD then recruits a protein called Fas-associated protein with death domain (FADD), which then sequentially activates caspase-8 and caspase-3, and thus apoptosis. Alternatively, TNF-α can activate mitochondria to sequentially release ROS, cytochrome c, and Bax, leading to activation of caspase-9 and caspase-3 and thus apoptosis. Some of the miRNAs can inhibit apoptosis by targeting the death-receptor pathway including miR-21, miR-24, and miR-200c.
p53 has the ability to activate intrinsic and extrinsic pathways of apoptosis by inducing transcription of several proteins like Puma, Bid, Bax, TRAIL-R2, and CD95.
Some inhibitors of apoptosis proteins (IAPs) can inhibit apoptosis indirectly (such as cIAP1/BIRC2, cIAP2/BIRC3) or inhibit caspase directly, such as XIAP/BIRC4 (inhibits caspase-3, -7, -9), and Bruce/BIRC6 (inhibits caspase-3, -6, -7, -8, -9).
Any alterations or abnormalities occurring in apoptotic processes contribute to development of human diseases and malignancies especially cancer.
References:
1.Yağmur Kiraz, Aysun Adan, Melis Kartal Yandim, et al. Major apoptotic mechanisms and genes involved in apoptosis[J]. Tumor Biology, 2016, 37(7):8471.
2.Aggarwal B B, Gupta S C, Kim J H. Historical perspectives on tumor necrosis factor and its superfamily: 25 years later, a golden journey.[J]. Blood, 2012, 119(3):651.
3.Ashkenazi A, Fairbrother W J, Leverson J D, et al. From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors[J]. Nature Reviews Drug Discovery, 2017.
4.McIlwain D R, Berger T, Mak T W. Caspase functions in cell death and disease[J]. Cold Spring Harbor perspectives in biology, 2013, 5(4): a008656.
5.Ola M S, Nawaz M, Ahsan H. Role of Bcl-2 family proteins and caspases in the regulation of apoptosis[J]. Molecular and cellular biochemistry, 2011, 351(1-2): 41-58.
- Caspase(102)
- 14.3.3 Proteins(2)
- Apoptosis Inducers(45)
- Bax(7)
- Bcl-2 Family(122)
- Bcl-xL(8)
- c-RET(9)
- IAP(27)
- KEAP1-Nrf2(67)
- MDM2(15)
- p53(128)
- PC-PLC(5)
- PKD(8)
- RasGAP (Ras- P21)(1)
- Survivin(8)
- Thymidylate Synthase(10)
- TNF-α(151)
- Other Apoptosis(900)
- Apoptosis Detection
- Caspase Substrate
- APC(6)
- PD-1/PD-L1 interaction(91)
- ASK1(3)
- PAR4(2)
- RIP kinase(52)
- FKBP(20)
- Pyroptosis(32)
Apoptosis 相关产品(2721)
- GC70289AC-VEID-CHO TFA纯度: >98.00%
AC-VEID-CHO TFA是一种肽衍生的caspase抑制剂,对caspase -6、caspase -3和caspase -7具有抑制作用,IC50值分别为16.2 nM、13.6 nM和162.1 nM。
- GC70658C5 LenalidomideCAS: 191732-70-4纯度: 不显示
C5 Lenalidomide(来那度胺5'-胺)是一种沙利度胺类似物,是TNF-α产生的强效抑制剂(在LPS刺激的人PBMC中IC50=100μM)。
- GC70733ABT-510 acetateCAS: 442526-87-6纯度: >99.00%
ABT-510 acetate是一种抗血管生成TSP肽(血小板反应蛋白-1类似物),在上皮性卵巢癌症原位同基因模型中诱导细胞凋亡并抑制卵巢肿瘤生长。
- GC70853Broussochalcone ACAS: 99217-68-2纯度: >97.00%
Broussochalcone A是黄嘌呤氧化酶的抗氧化剂和抑制剂(IC50=2.21 μM),具有清除自由基的活性。
| 货号 | 产品名称 | CAS号 | 纯度 | 结构 |
|---|---|---|---|---|
| GC70289 | AC-VEID-CHO TFA | - | >98.00% | |
AC-VEID-CHO TFA是一种肽衍生的caspase抑制剂,对caspase -6、caspase -3和caspase -7具有抑制作用,IC50值分别为16.2 nM、13.6 nM和162.1 nM。 | ||||
| GC70298 | Peginterferon beta-1a | 1211327-92-2 | 不显示 | |
Peginterferon β-1a是第一个聚乙二醇化的干扰素β -1a分子。 | ||||
| GC70332 | (+)-Erinacin A | 156101-08-5 | >99.00% | |
(+)-Erinacin A是一种抗癌化合物,可以从蘑菇猴头菇中分离出来。 | ||||
| GC70388 | Justicidin B | 17951-19-8 | >99.00% | |
Justicidin B是一种强效的抗癌木脂素和促凋亡剂。 | ||||
| GC70411 | Nrf2-Activator-12G | 1554271-18-9 | >99.00% | |
Nrf2-Activator-12G(compd 12g)是Nrf2的激活剂。 | ||||
| GC70418 | Cipepofol | 1637741-58-2 | >98.00% | |
Cipepofol(Ciprool)是一种新型的2,6-二取代苯酚衍生物,是GABAA受体的正变构调节剂和直接激动剂。 | ||||
| GC70520 | MIND4-17 | 345989-24-4 | >99.00% | |
MIND4-17是一种强效的NRF2激活剂,共价修饰Keap1的C151残基。 | ||||
| GC70570 | RH01386 | 301177-36-6 | >99.00% | |
RH01386是一种小分子,可以预防内质网应激(ERS)诱导的β细胞功能障碍和死亡,并抑制促凋亡基因的表达。 | ||||
| GC70584 | Actinomycin X2 | 18865-48-0 | >98.00% | |
Actinomycin X2(放线菌素V),由许多链霉菌属产生。 | ||||
| GC70658 | C5 Lenalidomide | 191732-70-4 | 不显示 | |
C5 Lenalidomide(来那度胺5'-胺)是一种沙利度胺类似物,是TNF-α产生的强效抑制剂(在LPS刺激的人PBMC中IC50=100μM)。 | ||||
| GC70659 | 9-cis-Retinoic acid-d5 | - | >98.00% | |
9-cis-Retinoic acid-d5是氘标记的9-顺式维甲酸。 | ||||
| GC70733 | ABT-510 acetate | 442526-87-6 | >99.00% | |
ABT-510 acetate是一种抗血管生成TSP肽(血小板反应蛋白-1类似物),在上皮性卵巢癌症原位同基因模型中诱导细胞凋亡并抑制卵巢肿瘤生长。 | ||||
| GC70742 | Betamethasone-d5-1 | 2244574-92-1 | 不显示 | |
βmethasone-d5-1氘标记为倍他米松。 | ||||
| GC70753 | PDK4-IN-1 | 2310262-10-1 | >98.00% | |
PDK4-IN-1是一种蒽醌衍生物和一种强效的口服活性丙酮酸脱氢酶激酶4(PDK4)抑制剂,IC50值为84nM。 | ||||
| GC70756 | Cytarabine-d2 | 40632-26-6 | >98.00% | |
Cytarabine-d2是氘标记的阿糖胞苷。 | ||||
| GC70759 | AQX-435 | 1619983-52-6 | >99.00% | |
AQX-435是一种强效的SHIP1磷酸酶激活剂。 | ||||
| GC70853 | Broussochalcone A | 99217-68-2 | >97.00% | |
Broussochalcone A是黄嘌呤氧化酶的抗氧化剂和抑制剂(IC50=2.21 μM),具有清除自由基的活性。 | ||||
| GC70868 | Nrf2 activator-3 | 2766570-23-2 | >98.00% | |
Nrf2 activator-3是一种有效的Nrf2激活剂。 | ||||
| GC70875 | RIPK1-IN-9 | 2682889-57-0 | 不显示 | |
RIPK1-IN-9(实施例45)是一种二氢萘啶酮化合物,是一种强效且选择性的RIPK1抑制剂。 | ||||
| GC70941 | ISIS 104838 sodium | - | >93.00% | |
ISIS 104838 sodium是一种反义寡核苷酸药物,可减少肿瘤坏死因子(TNF-α)的产生 | ||||
| GC71008 | BBR-BODIPY | 2456476-47-2 | >98.00% | |
BBR-BODIPY是一种荧光探针,可以筛选其与目标细胞的相互作用。 | ||||
| GC71031 | Nrf2 activator-6 | 2728780-74-1 | 不显示 | |
Nrf2 activator-6四氢异喹啉化合物是Nrf2活化剂。 | ||||
| GC71050 | Oditrasertib | 2252271-93-3 | >98.00% | |
Oditrasertib是一种IC50值低于100nM的受体相互作用蛋白激酶1(RIPK1)抑制剂。 | ||||
| GC71072 | NXPZ-2 | 2254492-08-3 | >98.00% | |
NXPZ-2是一种口服活性Keap1-Nrf2蛋白-蛋白相互作用(PPI)抑制剂,Ki值为95 nM,EC50值为120和170 nM。 | ||||
